ATE359809T1 - Gefriergetrocknete hgf-präparationen - Google Patents

Gefriergetrocknete hgf-präparationen

Info

Publication number
ATE359809T1
ATE359809T1 AT00935503T AT00935503T ATE359809T1 AT E359809 T1 ATE359809 T1 AT E359809T1 AT 00935503 T AT00935503 T AT 00935503T AT 00935503 T AT00935503 T AT 00935503T AT E359809 T1 ATE359809 T1 AT E359809T1
Authority
AT
Austria
Prior art keywords
freeze
growth factor
hepatocyte growth
aqueous solution
solution containing
Prior art date
Application number
AT00935503T
Other languages
English (en)
Inventor
M Chiba
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE359809T1 publication Critical patent/ATE359809T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00935503T 1999-05-31 2000-05-31 Gefriergetrocknete hgf-präparationen ATE359809T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15176999 1999-05-31

Publications (1)

Publication Number Publication Date
ATE359809T1 true ATE359809T1 (de) 2007-05-15

Family

ID=15525900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935503T ATE359809T1 (de) 1999-05-31 2000-05-31 Gefriergetrocknete hgf-präparationen

Country Status (11)

Country Link
EP (1) EP1180368B1 (de)
JP (1) JP4635340B2 (de)
KR (1) KR100767473B1 (de)
CN (1) CN100448482C (de)
AT (1) ATE359809T1 (de)
AU (1) AU5103200A (de)
CA (1) CA2375779A1 (de)
DE (1) DE60034445T2 (de)
ES (1) ES2408784T3 (de)
HK (1) HK1044471A1 (de)
WO (1) WO2000072873A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE60317822D1 (de) * 2002-10-29 2008-01-10 Alza Corp Stabilisierte feste polypeptidpartikel
KR20120104619A (ko) * 2003-08-14 2012-09-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
CN100345590C (zh) * 2003-08-14 2007-10-31 福建广生堂药业有限公司 包含促肝细胞生长素和干扰素的口含片
ATE455861T1 (de) 2004-05-04 2010-02-15 Novo Nordisk Healthcare Ag O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CN100464735C (zh) * 2006-08-02 2009-03-04 沈阳斯佳科技发展有限公司 促肝细胞生长素水针制剂的制备方法
CN100525833C (zh) * 2007-09-21 2009-08-12 南京大学 右旋糖苷40/多肽冻干粉针剂成型的方法
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN101670092B (zh) * 2009-09-01 2012-02-08 广东隆赋药业有限公司 一种注射用促肝细胞生长素冻干粉针剂的制备方法
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2849755A1 (de) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
EP2849754B1 (de) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, ein xanthinderivat als dpp-4-hemmer, zur verwendung bei der behandlung von sirs und/oder sepsis
WO2014081443A1 (en) 2012-11-20 2014-05-30 Fresenius Kabi Usa, Llc Caspofungin acetate formulations
CN106456695B (zh) * 2014-04-28 2019-11-12 卫材R&D管理有限公司 Hgf的冻干配制品
CN104013974A (zh) * 2014-06-11 2014-09-03 中国人民解放军军事医学科学院放射与辐射医学研究所 肝细胞生长因子基因在制备用于预防和/或治疗疼痛药物中的应用
CN106714823A (zh) 2014-09-10 2017-05-24 克霖固鲁制药股份有限公司 适合神经系统疾病的治疗的hgf制剂
CN105521483A (zh) * 2014-09-30 2016-04-27 陕西艾美雅生物科技有限公司 复合生物活性因子的冻干方法及冻干粉
KR20170079409A (ko) * 2015-12-30 2017-07-10 한미약품 주식회사 지속형 인간 성장 호르몬 결합체의 신규 액상 제제
RU2747977C2 (ru) 2016-03-17 2021-05-18 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения активного фактора роста гепатоцитов (hgf)
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
EP4337243A1 (de) 2021-05-14 2024-03-20 Claris Biotherapeutics, Inc. Zusammensetzungen von wachstumsfaktor zur behandlung von augenerkrankungen
CN116298244B (zh) * 2023-02-08 2025-10-10 安徽大千生物工程有限公司 一种总抗氧化物状态测定试剂盒及其制备、使用方法
CN120713840B (zh) * 2025-03-26 2025-11-25 天士力医药集团股份有限公司 一种PEG-hmFGF-21注射液及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200069A (nl) * 1982-01-11 1983-08-01 Philips Nv Weergeefinrichting met vloeibaar kristal.
WO1990012029A1 (en) * 1989-04-11 1990-10-18 Immunobiology Research Institute, Inc. Lyophilized peptide formulations
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JP3697460B2 (ja) * 1992-07-17 2005-09-21 敏一 中村 Ｈｇｆ含有製剤
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
CN102416176A (zh) * 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren

Also Published As

Publication number Publication date
CA2375779A1 (en) 2000-12-07
DE60034445T2 (de) 2008-01-03
WO2000072873A1 (fr) 2000-12-07
CN100448482C (zh) 2009-01-07
KR20020064141A (ko) 2002-08-07
EP1180368A1 (de) 2002-02-20
EP1180368B1 (de) 2007-04-18
DE60034445D1 (de) 2007-05-31
KR100767473B1 (ko) 2007-10-17
HK1044471A1 (en) 2002-10-25
ES2408784T3 (es) 2013-06-21
CN1367703A (zh) 2002-09-04
AU5103200A (en) 2000-12-18
JP4635340B2 (ja) 2011-02-23
EP1180368A4 (de) 2004-03-24

Similar Documents

Publication Publication Date Title
DE60034445D1 (de) Gefriergetrocknete hgf-präparationen
ES2263450T3 (es) Preparaciones de g-csf estabilizadas a largo plazo.
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
CA2226548A1 (en) Lyophilized hepatocyte growth factor preparations
KR920019371A (ko) 안정화된 인자 ⅷ 제제
FI903440A0 (fi) Stabiliserade fgf-sammansaettningar och foerfarande foer deras framstaellning.
PT1121144E (pt) Preparados de insulina concentrada estavel para administracao pulmonar
PT943326E (pt) Composicao em po para administracao nasal
PT86810B (pt) Processo para a preparacao de complexos estaveis de interferao
EP1260230A1 (de) Langfristig stabilisierte präparate
ATE203411T1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
RU2001108569A (ru) Стабилизированная фармацевтическая композиция в лиофилизированной форме
CA2234724A1 (en) Stable pharmaceutical forms of administration containing parathyroid hormone
ES2224917T1 (es) Composiciones farmaceuticas de agente fibrinolitico.
DK0490549T3 (da) Stabilisering af calcitonin-holdige farmaceutiske præparater
DK0973546T3 (da) Stabiliserede formuleringer med human papillomavirus
RU2004133349A (ru) Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата
KR950024769A (ko) 고농도 tcf 제제
DE60117248D1 (de) Parenterale lösung enthaltend amiodaron
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
DE69835165D1 (de) Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator
EP1103269A4 (de) Herstellungen zur verabreichung des hepatozyten wachstumsfaktor
ATE126064T1 (de) Arzneizusammensetzungen zur rektalen verabreichung enthaltend gefriergetrocknetes calcitonin.
DE68902755D1 (de) Antineoplastische formulierungen.
WO2000051603A3 (en) Compositions of remifentanil

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties